60 Degrees Pharmaceuticals To Present Data On Interim Analysis From Its Clinical Trial Of Tafenoquine On Oct. 6

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) will present the results of an interim analysis from its clinical trial evaluating tafenoquine in patients with severe babesiosis on October 6, 2026. The company focuses on developing new medicines for vector-borne diseases.